biologic (etanercept) (all strong recommendations [Table 5 Active PsA with comorbidities (Table 6 Active PsA in OSM-and biologic treatment-naive patients with concomitant diabetes. In patients with active PsA with concomitant active diabetes who have not received OSM or biologic treatment, an OSM other than MTX is recommended over a TNFi biologic, due to the concern about the higher prevalence of fatty liver disease and liver toxicity with MTX use in this patient population  (Table 6 Active PsA